Drugs / STSG-0002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05760781 | Apr → Dec 2023 | chronic hepatitis B virus infection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Terminated | No outcome recorded |
| Phase 2 | NCT05760703 | Apr → Dec 2023 | chronic hepatitis B virus infection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STSG-0002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05760781 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT05760703 ↗ |